Targeting fungi: a challenge.
Invasive fungal infections are more commonly identified in various categories of patients, mainly in cancer patients but also in those undergoing organ transplantation, patients in intensive care units, and those with AIDS. There is a great need to increase the awareness of practitioners who are still underestimating the morbidity and mortality relating to invasive fungal infections, and to stress the economic burden for the society and healthcare systems of invasive fungal infections. The list of fungal pathogens causing life-threatening complications has also increased recently, with the emergence of unusual fungi being more frequently identified in such settings. Early diagnosis of invasive fungal infections is still a major challenge for the clinician at the bedside. Identification of state-of-the-art management is also a difficult task for the clinical scientist involved in the assessment of optimal strategies to prevent and to treat those invasive fungal infections, although major progress has occurred in the last 5 years with the development of new, safe, and effective antifungal agents. Empiric therapy remains a very controversial issue that should be further investigated in high-quality clinical trials. Overall, clinical research in this difficult field requires independent and objective analysis; only large multicenter clinical trials can address these critical issues and rapidly provide convincing results leading to a better prognosis of patients with invasive fungal infections. These complications still represent too often an obstacle to successful control of severe underlying diseases. Clinical research on the appropriate ways to target fungi will not only define state-of-the-art management but also identify ineffective or redundant treatments. Such an approach will make a substantial contribution to the care of the high-risk patients within the next decade and will preserve our capacity for medical excellence.
Meunier
F
F
EORTC Central Office, Data Center, Brussels, Belgium.
D017088:AIDS-Related Opportunistic Infections; D000935:Antifungal Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003422:Critical Care; D005658:Fungi / Q000472:pathogenicity; D006801:Humans; D016867:Immunocompromised Host; D015337:Multicenter Studies as Topic; D009181:Mycoses / Q000175:diagnosis / Q000188:drug therapy / Q000191:economics / Q000517:prevention & control; D009369:Neoplasms / Q000150:complications; D009894:Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy / Q000191:economics / Q000517:prevention & control; D016377:Organ Transplantation; D011379:Prognosis
D000935:Antifungal Agents